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Abstract
Copper/zinc superoxide dismutase (CuZnSOD; SOD1) is widely considered as a potential 
therapeutic candidate for pathologies involving oxidative stress, but its application has been 
greatly hindered by delivery issues. In our previous study, nano-formulated SOD1 (cl-nanozyme) 
was shown to decrease infarct volume and improve sensorimotor functions after single 
intravenous (IV) injection in a rat middle cerebral artery occlusion (MCAO) model of ischemia/
reperfusion (I/R) injury. However, it remained unclear how cl-nanozyme was able to deliver 
SOD1 to the brain and exert therapeutic efficacy. Present study aims to answer this question by 
exploring micro-distribution pattern of cl-nanozyme in the rat brain after stroke. 
Immunohistochemistry studies demonstrated cl-nanozyme co-localization with fibrin along 
damaged arteries and capillaries in the ischemic hemisphere. We further found that cl-nanozyme 
can be cross-linked into thrombi formed after I/R injury in the brain, and this effect is independent 
of animal species (rat/mouse) used for modeling I/R injury. This work is also the first report 
reinforcing therapeutic potential of cl-nanozyme in a well-characterized mouse MCAO model of 
I/R injury.
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Introduction
Stroke affects 7 million people, and continues to kill over a hundred thousand people 
annually in the United States alone [1]. Main causes of brain tissue damage during transient 
ischemic stroke are ischemic and reperfusion injuries. Ischemic injury results from lack of 
glucose and oxygen when blood flow to the brain is blocked [2]. Reperfusion injury results 
from the detrimental action of reactive oxygen species (ROS) on brain tissue after blood 
flow is restored [3].
Antioxidant enzymes are endogenous tools for cells to scavenge ROS. However, their 
expression is often inhibited during stroke [4, 5], rendering antioxidant activity far less than 
sufficient for complete removal of excess ROS. Therefore, supplementation of antioxidant 
enzymes to the brain is a potential therapeutic strategy for this disease [6]. Their action 
would be especially beneficial for rescuing the salvageable penumbra since oxidative stress 
is the main mechanism of tissue damage in this area [7]. A direct use of anti-oxidant 
enzymes as therapy for stroke is not plausible because of its short half-life in the blood and 
poor permeability across the blood-brain barrier (BBB) and cellular membranes [8]. Even 
though BBB can be partially compromised during and after stroke, it still remains the key 
impediment for CNS transport of enzymes [9, 10]. Multiple strategies have been explored 
for delivery of functional antioxidant enzymes to the brain, including cationic liposomes, 
fusion proteins with peptide transduction domains, poly(ethyelene glycol)-protein 
conjugates (PEGylated protein) and encapsulation into poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles [11–18]. However, each of these approaches has limitations that precluded 
their successful clinical use as discussed in our previous work [19]. Briefly, loading of 
enzymes into solid or hollow nanoparticles often resulted in loss of activity and/or 
unsatisfactory loading efficiency (32% in the case of SOD1 liposomes [20]), and 
PEGylation usually decreases enzyme permeability across BBB [13].
We have demonstrated a different approach for encapsulation and delivery of antioxidant 
enzymes to the brain [19, 21, 22]. This approach is based on incorporation of an antioxidant 
enzyme, such as SOD1, into nano-sized polyion complexes with cationic block copolymers 
(“nanozymes”). Nanozymes are core-shell structured nanoparticles with the polyion 
complex core consisting of charge-neutralized polycation chains and protein globules, and 
the shell consisting of PEG chains. Primary amine groups in the core were cross-linked (cl) 
using low molecular mass chemical cross-linkers to form cl-nanozyme and further purified 
to improve sample homogeneity by removing non-cl-nanozymes [19]. This formulation is 
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essentially a covalently cross-linked polyion complex formed by SOD1 and methoxy-
poly(ethylene glycol)-b-poly(l-lysine) (PEG-pLL, Figure S1). Some of the key advantages 
of this strategy include high (100%) loading efficiency (owing to the formation of 
stoichiometric complexes) and instantaneous enzyme availability for catalysis precluding the 
need for its release, since superoxide anions are small enough to freely diffuse into the 
enzymatic core of the particle. This is a distinct advantage in scavenging ROS in the acute 
phase of diseases caused by oxidative stress, because the time window for antioxidant 
enzymes to work in these scenarios are usually narrow, and “fast acting” formulations like 
cl-nanozyme are consequently favored over those requiring drug release mechanisms.
The initial in vivo proof of concept for nanozyme transport to CNS was obtained by us using 
cl-nanozymes carrying butyrylcholinesterase, SOD1, or catalase [22, 23]. Compared to 
PEGylated SOD1 which poorly enters cells, SOD1 nanozyme was transported into neuronal 
cells and was superior to PEGylated SOD in depleting intracellular ROS and inhibiting 
Angiotensin II signaling in vitro and in vivo [24, 25]. Catalase nanozymes demonstrated 
neuroprotective effects in an animal model of Parkinson’s disease (PD) [26, 27]. Our most 
recent results demonstrated the therapeutic efficacy of purified SOD1 cl-nanozyme in a rat 
middle cerebral artery occlusion (MCAO) model of I/R injury [19] by decreasing infarct 
volume and improving sensorimotor functions after a single IV bolus. Similar to other 
reports using nano-formulated SOD1 for the treatment of stroke [15, 18], we did not 
specifically investigate how this approach was able to exert the observed therapeutic effect 
[19]. However, understanding this mechanism can be essential for improving therapeutic 
potential of SOD1 nanozyme formulation and for discovery of more applications of the 
nanozyme delivery platform.
In the present work, we demonstrate that cl-nanozyme accumulated predominantly within 
the injured vasculature and co-localized with fibrin after stroke. This suggests one possible 
mechanism where cl-nanozyme passively target to damaged brain vasculature, and locally 
protect the neurovascular unit as an entire entity. To evaluate this finding from a 
translational perspective and investigate the validity of our findings in another animal 
model, we tested the same cl-nanozyme formulation in a well-characterized mouse model of 
stroke, and again observed significant reduction of infarct size. In vitro thrombus 
incorporation assay in the mouse plasma further supported our major hypothesis that cl-
nanozyme can be actively incorporated into growing thrombus formed during or after stroke.
Materials and Methods
Materials
3,3’-Diaminobenzidine (DAB), SOD1, and 2,3,5-triphenyltetrazolium chloride (TTC) were 
purchased from Sigma-Aldrich. PEG113-pLL51 was purchased from Alamanda Polymers™; 
Bovine serum albumin (BSA), ethanol, ethylenediaminetetraacetic acid (EDTA), 3,3´- 
dithiobis(sulfosuccinimidylpropionate) (DTSSP), 10% neutral buffered formalin, 
trichloroacetic acid (TCA) were purchased from Thermo Fisher Scientific. AlexaFluor® 
secondary antibodies, and Hoechst 43580 were purchased from Life Technologies; C57BL/6 
mouse plasma was purchased from Molecular Innovations. All reagents and chemicals were 
used as received.
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Charles River Laboratories supplied 8-week-old male Sprague-Dawley rats (250–300 g), 
and 12-week-old male C57BL/6 mice (20–28 g). Animals were housed and humanely 
handled in accordance with the Principles of Animal Care outlined by National Institutes of 
Health. They were allowed free access to food and water and were maintained under 
temperature, humidity, and light-controlled conditions. Institutional Animal Care and Use 
Committees (IACUC) of University of Nebraska Medical Center (UNMC) and the 
University of North Carolina at Chapel Hill approved all experiments involving animal 
subjects.
MCAO model of transient ischemic stroke in rats
Brain ischemia was modeled by transient MCAO method as described previously [28]. Rats 
were anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg) cocktail and isoflurane 
(5% v/v for induction and 0.5% v/v during surgery). Rectal temperature was maintained at 
about 37 °C throughout the surgery using a homeothermic monitor (Harvard Apparatus, 
UK). Animals were prepared for surgery according to IACUC recommendations. The right 
common carotid artery was exposed and occluded using a silicon rubber-coated 
monofilament for MCAO. Filament was inserted through the incision into internal carotid 
artery (ICA) and further until reaching the bifurcation of MCA. Tip occluded the entrance to 
MCA and blocked blood supply to part of the right brain hemisphere (referred to as the 
ischemic hemisphere). Filament was carefully withdrawn after 1 hour. Sham surgery was 
performed as described above without filament insertion. After the surgery, animals were 
returned to their cages and allowed free access to water and food. At the time of reperfusion, 
10,000 U/ kg of native SOD1 or cl-nanozyme (n = 10 in each group) were IV injected under 
anesthesia. Rats were sacrificed 3 or 24 h post-reperfusion, and perfused with 4% 
paraformaldehyde solution for histology analysis.
Histology and Immunohistochemistry
Tissue toxicity of cl-nanozyme was assessed by hematoxylin and eosin (H&E) staining of 
liver, spleen, kidney, and lung tissues. Tissue samples were dissected and fixed in 10% 
neutral buffered formalin before embedded in paraffin. Five µm thick tissue sections were 
processed and stained according to standard protocol used by Tissue Sciences core facility at 
UNMC. Cl-nanozymes were visualized in peripheral organs using DAB. Tissue samples 
were prepared as described above. For detection of cl-nanozyme in liver, spleen, kidney, and 
lung, respective tissue sections were incubated at 4 °C overnight with rabbit anti-PEG 
antibody (1:500, Abcam, MA), followed by incubation with secondary biotinylated goat 
anti-mouse antibodies and VecStain Elite kit (Vector Laboratories, CA). DAB color 
generation system was used as described previously [29] for chromogenic visualization. 
Fluorescent immunohistochemistry study was performed on tissues perfused with PBS 
followed by 10% neutral buffered formalin. To visualize cl-nanozyme in the liver and brain, 
tissue sections were stained using rabbit anti-PEG antibody (Abcam, CA) diluted 1:200 and 
1:100, respectively. Hepatocytes were detected with polyclonal chicken anti-albumin 
antibody (1:100, Sigma Aldrich, MO). CD68+ cells in the brain (infiltrating monocytes), 
liver (Kupffer cells) and spleen (splenic macrophages) were visualized using monoclonal 
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mouse anti-CD68 antibody (1:40 Abcam, MA). Brain microvessels were visualized using 
monoclonal mouse anti-CD31 antibody (1:30, AbD Serotec, NC); neurons were visualized 
using monoclonal mouse anti-neurofilament 70kDa (NF-L) antibody (1:200, Millipore, CA); 
fibrin deposits after stroke were visualized using mouse anti-fibrin antibody (1:50, Abcam, 
MA). Treatment with primary antibodies was followed by treatment with secondary 
antibodies: AlexaFluor 594 goat anti-chicken, AlexaFluor 594 goat anti-mouse, and 
AlexaFluor 488 goat anti-rabbit, and AlexaFluor 647 goat anti-mouse. Nuclei were 
visualized using 2.5µg/ml Hoechst 43580 solution. Immunofluorescence were detected using 
Zeiss 710 Confocal Laser Scanning Microscope and images were analyzed using Zeiss Zen 
software and ImageJ software (National Institute of Health, MD).
Preparation of 125I-labeled Proteins and Cl-nanozyme
Native SOD1, fibrinogen, BSA, or cl-nanozyme were radioactively labeled with 125I using 
chloramine-T method as previously described [30]. Briefly, 5 µg of protein or equivalent 
amount of cl-nanozyme was mixed with 0.5 mCi Na125I (PerkinElmer, MA) in a final 
volume of 40 µL in sodium phosphate buffer (0.25 M, pH=7.5). Five µL freshly-made 
chloramine-T solution (2 µg/µL in sodium phosphate buffer) was added to the mixture. After 
60 s incubation under constant mixing, the 125I-labeled samples were purified using Illustra 
NAP-5 desalting columns (GE Healthcare, NJ). Fractions were collected in Eppendorf tubes 
pretreated with 1% BSA in Lactated Ringer’s solution (1% BSA-LR) to prevent non-
specific adsorbance. Radioactivity was measured using a PerkinElmer γ-counter. TCA 
precipitation was conducted to determine the 125I association of labeled samples. Briefly, 1 
µL of collected fractions was added to 0.5 mL of 1% BSA-LR and then precipitated in 0.5 
mL of 30% TCA followed by centrifugation at 5000 ×g for 10 min at 4 °C. The resulting 
supernatant and pellet were measured in the γ-counter and the values were used to calculate 
the %radioactivity that precipitated with acid (% protein bound-125I = [CPMpellet /(CPMpellet 
+ CPMsupernatant)]*100%). Samples containing >100,000 cpm/µL of radioactivity and > 
90% TCA precipitation were used for animal studies.
Biodistribution and Serum Clearance in Mice
Twelve-week-old male C57BL/6 mice were anesthetized by intraperitoneal (IP) injection of 
0.2 mL of urethane (4.0 g/kg). Approximately 500,000 CPM of radiolabeled samples were 
injected IV via the jugular vein with 0.2 mL of 1% BSA-LR. For the biodistribution study, 
the abdomen and rib cage were opened and venous blood was collected by cardiac puncture 
1 hour post-injection. Then, 20 mL of PBS was perfused through the left ventricle of the 
heart. At the end of study, organs were dissected and wet-weighed. For the serum clearance 
study, blood from the pre-exposed carotid artery was collected at various time points after 
injection. Serum was separated from whole blood by centrifugation at 5400 ×g for 10 min at 
4 °C. Levels of radioactivity were measured in the γ-counter. To calculate serum clearance, 
the level of radioactivity was expressed relative to the amount injected (%Inj/mL) and these 
values were plotted against time (min) to construct the serum concentration vs. time curve.
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MCAO Model of Transient Ischemic Stroke in Mice
All mice were randomly assigned before surgery into one of the following groups: cl-
nanozyme-treated group (n = 8), native SOD1-treated group (n = 8), or saline-treated group 
(n = 7). The mice were weighed and were subjected to 90 min of ischemia under isoflurane 
anesthesia (5% v/v for induction and 1.5% v/v during surgery) as previously described [31]. 
Briefly, rectal temperature was monitored maintained at approximately 37 °C during surgery 
using a homothermic heating system. A midline ventral neck incision was made, and 
unilateral MCAO was performed by inserting a silicone rubber coated monofilament into the 
right internal carotid artery 6 mm from the internal carotid/pterygopalatine artery bifurcation 
via an external carotid artery stump. At the time of reperfusion, 10,000 U/ kg of treatment 
solutions were IV injected under anesthesia.
TTC Staining and Brain Infarct Volume Quantification
After 90 minutes of ischemia and 24 hours of reperfusion, the mice were euthanized and the 
brains were chilled at −80 °C for 4 minutes to slightly harden the tissue. Five 2-mm-thick 
coronal sections were cut from the olfactory bulb to the cerebellum and then stained with 
1.5% TTC in PBS (pH=7.4). The sections in TTC solution were incubated in a water bath 
maintained at 37 °C for 30 minutes, then transferred to a 10% phosphate-buffered formalin 
solution and incubated overnight at 4 °C before pictures were taken for analysis. The infarct 
volumes were calculated blinded to the treatment given, and the infarct size in each of the 
five slices was quantified using the Image J software. In addition to total hemisphere, the 
infarct areas were determined separately for cortex and caudoputamen in each slice. Then 
the infarct areas on each slice were summed up and multiplied by thickness to calculate 
infarct volumes. The infarct volumes were calculated using Swanson’s method [32] and 
processed as % contralateral hemisphere to avoid mis-measurements secondary to edema.
Thrombus Incorporation Assay in Mouse Plasma
One hundred thousand CPM of 125I-labeled fibrinogen, BSA, native SOD1, and cl-
nanozyme were added into an Eppendorf tube containing 1 mL C57BL/6 mouse Lithium 
heparin-stabilized plasma (Innovative Research, MI). Half mg of protamine sulfate was then 
added to neutralize heparin and allow thrombus formation. The tube was incubated on a 
rotary-shaker for 24 h at 4 °C before centrifugation at 5000×g for 10 min. Serum was 
separated from the white thrombus at the bottom of the tube, and then subjected to TCA 
precipitation assay to correct for error caused by 125I dissociation during incubation as 
described above. Percentage of samples sequestered in the thrombus compartment were 
calculated using the following formula: %Thrombus Incorporation = [CPMthrombus /
(CPMthrombus + CPMserum)]*100%.
Statistical Analysis
The randomization code was broken in the mice stroke therapeutic efficacy study after 
acquiring all the data. Statistical analysis was done using Prism 5.0 software (GraphPad, 
CA). Unpaired Student's t-test was used for two groups, and one-way ANOVA followed by 
Tukey’s multiple comparison test for groups of three and above. A minimum pvalue of 0.05 
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was estimated as the significance level. Results of all experiments are presented as mean ± 
standard error of the mean (SEM).
Results
Cl-nanozyme Tissue Distribution in the Rat MCAO Model of I/R Injury
In our previous paper [19] reporting synthesis and purification of cl-nanozyme, we have 
demonstrated decreased infarct volume and improved sensorimotor functions after a single 
IV injection in a rat MCAO model. To gain insight into the mechanism of cl-nanozyme’s 
therapeutic efficacy, we studied its micro-distribution in the same model. 
Immunohistochemistry (IHC) analysis revealed accumulation of cl-nanozyme primarily in 
the ipsilateral hemisphere in the area of infarct at 3h post-reperfusion. (Figure S2).
Cl-nanozyme localized primarily within blood vessels, as shown by fluorescent double 
staining for cl-nanozyme and endothelial marker PECAM-1 in Figure 1A. Cl-nanozyme 
staining outside the blood vessel in brain parenchyma was primarily seen in the infarct 
region of the ipsilateral hemisphere. Cl-nanozyme co-localized with neither neurons nor 
activated mononuclear phagocytes (Figure S2).
We further hypothesized that cl-nanozyme co-localize with damaged blood vessels, since its 
signal was most prominent in infarct regions. Evidence for this hypothesis is shown in 
Figure 2. During the MCAO procedure, occlusion is created by filament insertion into the 
lumen along the internal carotid artery. Figure 2A is a confocal micrograph of a coronal 
brain section across a portion of internal carotid artery where the filament tip was positioned 
(Figure 2D).
The filament tip had damaged the artery during filament insertion and/or occlusion, as 
suggested by discontinuous nuclear staining around the luminal side of the artery (Figure 
2C), and cl-nanozyme co-localized with these damaged portions of the artery (Figure2B and 
2C). No cl-nanozyme signal was observed in the contralateral hemisphere where the internal 
carotid artery was not damaged, as shown in dotted box, Figure 2B. In infarcted brain 
regions, cl-nanozyme co-localized with fibrin, a protein involved in blood clotting 
(Figure1B and 1C), which further supports our hypothesis that cl-nanozyme localizes in 
damaged blood vessels. Interestingly, while most cl-nanozyme signal co-localized with 
fibrin, not all capillaries with fibrin deposition sites showed cl-nanozyme accumulation 
(Figure 1C).
Peripheral organs were collected 24 hours after reperfusion, and histological examinations 
was performed to qualitatively study the disposition and any possible toxicity effects of cl-
nanozyme. H&E-stained tissue sections did not reveal any sign of acute toxicity (Figure S3). 
Analysis of cl-nanozyme distribution in select peripheral organs confirmed its presence in 
the liver and spleen, but not in lungs or kidneys at this time point (Figure 3A). Triple 
fluorescent immunostaining of the liver tissue revealed co-localization of cl-nanozyme with 
hepatocytes and Kupffer cells (Figure 3B). We noticed intense cl-nanozyme staining in areas 
between two adjacent hepatocytes indicative of its deposition in the bile canaliculi, 
suggesting a potential clearance mechanism via bile excretion. In addition to their 
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intracellular accumulation in hepatocytes, cl-nanozymes were also observed in liver 
sinusoids.
Cl-nanozyme Biodistribution and Serum Clearance in Mice
We studied biodistribution of native SOD1 and cl-nanozyme in healthy C57/B6 mice to 
determine the effects of formulating SOD1 on its biodistribution. One hour after injection, 
cl-nanozyme was found to accumulate in liver and spleen in significantly higher amounts 
than native SOD1, displaying 25- and 38-fold increases, respectively (Figure 4A). Changes 
in SOD1 accumulation in most other peripheral organs including heart, lung, and spine were 
significant but less drastic (less than 4-fold increase) compared to liver and spleen. 
However, cl-nanozyme accumulation in kidney was reduced by more than half compared to 
native SOD1 (35.4% vs. 88.3%). Notably, the brain uptake of cl-nanozyme was 2-fold 
higher than native SOD1 (0.0809% vs. 0.0406%) in healthy mice.
First-order kinetics was observed in the early phase of clearance for both substances, 
demonstrated by the statistically significant relation between log(%Inj/mL) and time (Figure 
4B). Serum half-life (t1/2) of native SOD1 and cl-nanozyme was 10.3 min and 33.8 min 
respectively, suggesting prolonged SOD1 circulation after formulation.
Therapeutic Effect of Cl-nanozyme in Mouse MCAO Model of I/R Injury
Cl-nanozymes administered at the onset of reperfusion in a mouse MCAO model of I/R 
injury resulted in reduced infarct volumes compared to groups treated with saline or native 
SOD1. Significantly reduced infarct volume was observed in all three brain regions analyzed 
(cortex: 35.0±7.0%; caudoputamen: 13.0±4.7%; hemisphere: 28.1±5. 6%) compared to 
those injected with saline (cortex: 69.8±3.7%; caudoputamen: 73.7±6.0%; hemisphere: 
61.5±6.8%) and native SOD1 (cortex: 59.3±7.7%; caudoputamen: 78.9±6.5%; hemisphere: 
57.1±6.9%), as shown in Figure 5. The mean infarct volume was slightly lower in the native 
SOD1-treated group than in saline-treated group, albeit this difference was not statistically 
significant. Interestingly, the protective effect of cl-nanozyme appears to be stronger in the 
caudoputamen area than in the cortex or entire hemisphere.
Thrombus Incorporation Assay
To directly evaluate the ability of cl-nanozyme and native SOD1 to be incorporated into 
white thrombi, we performed an in vitro thrombus incorporation assay using mouse plasma. 
After 24 h incubation at 4 °C, incorporation of native SOD1 into the thrombi (4.4±0.4%) 
was not significantly different from that of the negative control, BSA. However, 
significantly more cl-nanozyme (8.2±0.2%) was sequestered in the thrombus compartment 
(Figure 6). Fibrinogen was used as a positive control and showed 52±4% accumulation in 
the thrombi.
Discussion
Cl-nanozyme for delivery of antioxidant enzymes has been successfully used by us 
previously for the treatment of multiple pathologies involving oxidative damage [19, 21, 24, 
25, 33–35]. Specifically, its therapeutic effect in decreasing the infarct volume and 
Jiang et al. Page 8













improving sensorimotor functions upon single IV injection in a rat stroke model was 
demonstrated in our laboratory [19]. The present study continues to explore the mechanism 
by which cl-nanozyme exerted therapeutic efficacy.
The structure of cl-nanozyme does not include a brain targeting moiety. Thus, we did not 
expect it to cross a healthy BBB. Initially we believed that cl-nanozymes could possibly 
enter the brain via the disrupted BBB, a well-characterized phenomenon after brain I/R 
injury [36–38]. To our surprise, despite the observed therapeutic efficacy in the stroke 
model, we did not observe substantial evidence of cl-nanozyme crossing the BBB. In the 
IHC experiments, we did observe a considerable amount of cl-nanozyme signal associated 
with the infarct region of the brain, where the BBB is supposed to be disrupted. However, 
the majority of the signal was not associated with neurons or activated macrophages, but 
trapped inside the lumen of blood vessels. Although by design, our study does not exclude 
the possibility of a small portion of cl-nanozyme crossing the BBB and exerting therapeutic 
effect, the hypothesis of thrombus accumulation is apparently more plausible based on our 
observations. It also serves better on explaining why cl-nanozyme shows much better 
therapeutic efficacy compared to native SOD1, which can be tricky to explain based solely 
on the BBB disruption theory.
Our thrombus incorporation hypothesis is derived from the chemical composition of cl-
nanozyme, with its core structure being charge-neutralized pLL/SOD1 complex. The 
monomer of pLL, ε -lysine is capable of cross-linking into the thrombus by participating in 
biochemical reactions accompanying its formation [39]. Briefly, blood vessel damage 
activates platelets and initiates a cascade of tissue factor (TF) activation, which converts 
TFXIII to its active form, TFXIIIa. TFXIIIa is a transglutaminase which cross-links 
glutamine with the ε-amine group of lysine. Indeed, pLL has been proved to be a good 
substrate for transglutaminase and this reaction has been utilized to enzymatically produce 
pLL-protein conjugates [40]. Therefore it is not surprising to see this reaction occurring in 
vivo.
IHC data in the rat model strongly supported the thrombus incorporation hypothesis. Cl-
nanozyme was detected primarily in the infarct region in association with endothelial cells 
of the damaged brain vasculature. Intense cl-nanozyme signal was observed only in areas 
surrounding the injured internal carotid artery, but not the healthy one in the contralateral 
hemisphere (Figure 2B), confirming the selective nature of the association between cl-
nanozyme and damaged blood vessels. Evidence of cl-nanozyme and thrombus crosslinking 
was further supported by the co-localization of cl-nanozyme with fibrin, a major component 
in blood clots, in the capillaries of the infarct region.
Beyond the brain, we have also examined cl-nanozyme distribution in select peripheral 
organs. H&E data suggested that cl-nanozyme is not noticeably toxic after in vivo 
administration. This is a promising observation that supports further development of such 
nanoparticles for stroke therapy. IHC experiments found massive distribution of cl-
nanozyme into liver and spleen. This is generally in agreement with the known function of 
these organs in clearing particulate matter. Interestingly, a closer look at the liver slices 
revealed distribution of cl-nanozyme not only in Kupffer cells, but also in tube-shaped 
Jiang et al. Page 9













territories between two adjacent hepatocytes that resemble bile canaliculi. This particular 
staining pattern possibly indicates that cl-nanozyme is excreted through bile as part of its 
metabolic pathway. What we have detected in these structures is more likely to be metabolic 
products than intact cl-nanozymes, especially considering the time point of analysis (24 h 
after reperfusion) and the cleavable disulfide bond present in the cross-linker (DTSSP) used 
in this formulation. Notably, the rat liver has been reported to have rather high 
concentrations (10 mM) of reduced glutathione known to participate in disulfide reduction, 
which thereby may enhance degradation of the cl-nanozyme in the liver [19]. In addition to 
intra-hepatocyte accumulation, staining was also observed in the liver sinusoids. 
Considering the t1/2 of cl-nanozyme (33.8 min in mouse), it is unlikely that level of cl-
nanozyme in the blood is high at this time point, i.e. 24 h after administration. Presence of 
cl-nanozyme in liver sinusoids may result from pLL binding to liver tissue, possibly via the 
same mechanism by which they bind to damaged blood vessels in the brain, since most of 
the blood coagulation proteins are synthesized in the liver [41].
These results in the rat MCAO model indicate that the therapeutic effect of cl-nanozyme can 
be attributed to its specific accumulation into damaged blood vessels in the infarct region. In 
events where blood vessels were damaged, intrinsic mechanisms of thrombosis could take 
place and actively recruit cl-nanozyme into them, thereby effectively reducing oxidative 
stress generated at the vicinity of damaged sites. Such blood vessel damage could result 
either from mechanical force (filament damaging ICA) or I/R injury (endothelium damage), 
both occurring in the MCAO model of stroke and the latter can also take place after transient 
stroke suffered by human subjects [42]. Since this mechanism appears to be translatable to 
human patients, we moved forward and investigated utility of cl-nanozymes in a different 
species to determine if similar therapeutic outcomes can be achieved in the mouse model of 
I/R injury. Indeed, this work is the first report reinforcing therapeutic potential of cl-
nanozyme in a well-characterized mouse MCAO model [43].
Before evaluating cl-nanozyme in the mice MCAO model, we first conducted a 
comprehensive study to determine cl-nanozyme biodistribution in the early phase (1h) after 
injection. Similar to the rat model, we observed significantly increased sequestration of cl-
nanozyme in the liver and spleen compared to native SOD1. Reduced uptake of cl-
nanozyme in the kidney compared to that of native SOD1 (32 kDa) is in general agreement 
with the known function of kidney (glomerular filtration) in clearing small molecules with a 
molecular mass cutoff of ~40 kDa. Tissue distribution of protein is generally increased after 
formulation in most other organs, including a significant 2-fold increase in the brain. This 
increase probably resulted from a combination of decreased kidney accumulation and 
increased serum half-life as shown in Figure 4B.
Remarkably, cl-nanozyme administration resulted in significant reduction of infarct size in 
the mouse MCAO model compared to the native SOD1 group reinforcing its therapeutic 
potential in a second rodent model. Formation of micro-thrombi in capillaries after MCAO 
surgery is a well-documented phenomenon in rodent MCAO models [42, 44, 45]. 
Specifically, Zhang and colleagues [46] reported fibrin deposition primarily in the sub-
cortex region after acute ischemic stroke, which may explain why therapeutic effect of cl-
nanozyme is more pronounced in the caudoputamen compared to the cortex. Therefore, we 
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speculate that the mechanism of action of cl-nanozyme involves local protection of cerebral 
vasculature. Since the damaged brain endothelium in I/R injury is a site of intense ROS 
production [47], retention of cl-nanozyme in the sites of vascular damage and thrombus 
formation can facilitate its ability to scavenge local ROS and to subsequently mitigate 
detrimental effects of ROS on vasculature.
From a translational research perspective, clinically, different factors can contribute to local 
thrombus formation during the reperfusion phase of focal cerebral ischemia, as described by 
Virchow’s triad: reduction in cerebral blood flow, damage to the vessel wall, and 
hypercoagulability. These events can contribute to the occurrence of focal “no-reflow” 
phenomenon [48] and even thromboembolic complications in the sub-acute phase of 
ischemic stroke [49]. In our thrombus incorporation study, we clearly demonstrated that cl-
nanozyme can be actively incorporated into thrombus during their growth. This 
experimental set up is a simplified model where only white thrombi are formed. It can be 
postulated that in the scenario of clinical stroke where body temperature, blood cells, and 
platelets are all contributing to thrombus formation, the rate and extent of cl-nanozyme 
incorporation into thrombus could be faster and greater. By exploiting the “no-reflow” 
phenomenon and by passively accumulating at the site of injured arteries and microvessels 
after reperfusion, it is not surprising that cl-nanozyme exerted better therapeutic outcomes 
than native SOD1. Furthermore, passive targeting to sites of thrombus formation may open 
avenues for the delivery of agents that protect the endothelium from negative side effects of 
thrombolytics such as recombinant tissue plasminogen activator (rt-PA).
Two key works reported the use of particulate carriers for the delivery of SOD1 to treat 
stroke. Reddy and Labhasetwar demonstrated a 65% decrease in infarct volume compared to 
saline-treated group when SOD1 encapsulated in PLGA nanoparticles (NPs) was delivered 
via intracarotid (IC) injection to a rat MCAO model of stroke [15]. Interestingly, they also 
showed increased accumulation of HRP-loaded NPs in the ischemic hemisphere compared 
to its non-ischemic counterpart similar to our observation on increased accumulation of cl-
nanozyme in the ischemic hemisphere. The authors pointed out the need for further research 
to understand the mechanism of NP-mediated protection. Yun et al. also showed a 50–60% 
decrease in infarct volume when SOD1 was delivered (again via the IC route) using 3 
different nanoparticle platforms (liposomal SOD1, Polybutylcyanoacrylate-SOD1 and 
PLGA-SOD1 particles) in a mouse MCAO model of stoke [18]. SOD1 was conjugated to 
the distal end (mPEG2000-DSPE) of liposomes prepared using phosphatidylcholine, 
cholesterol, mPEG2000-DSPE, and MAL-PEG2000-DSPE (molar ratio of 55:39:4:2). These 
carriers were modified with anti-NMDA receptor antibodies for brain targeting, and was 
shown to protect the ischemic regions by suppressing caspase-3 activation.
Although the present study is not unique in exploring therapeutic effect of SOD1 nano-
formulations, it draws attention to the delivery of therapeutics to the neurovascular unit as a 
whole and in particular to the damaged brain endothelium, rather than neurons alone. Often 
researchers focus extensively on the delivery of therapeutics across the BBB to the brain 
parenchyma, a task that remains a formidable challenge in most cases. However, it can be 
not as formidable to target therapeutics to the BBB itself. Indeed, homeostatic interactions 
exist between endothelium and cerebral parenchyma, and the BBB has been considered to 
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be neuro-protective on its own by excreting neurotrophic factors in response to injury [50]. 
Our observations document that cl-nanozyme accumulates into damaged brain vasculature 
regions and probably exerts its effect mainly on brain vasculature rather than the 
parenchyma. It provides evidence that targeting therapeutics to the BBB itself could also be 
a viable therapeutic strategy. Another advantage of our approach is the use of IV 
administration route, which can be more desirable than IC from a translational perspective. 
This is made possible collaboratively by increased serum half-life and additional local 
retention at the damaged sites of vasculature. Moreover, our approach of drug administration 
after ischemic episode, as opposed to pretreatment with SOD1 formulations, as reviewed by 
Margaill et al.[6], is advantageous from translational standpoint as well.
Conclusion
In conclusion, the present study demonstrates the ability of cl-nanozyme to accumulate in 
damaged blood vessels. This allowed therapeutic cargo to exert its effect at the interface of 
blood and brain especially vulnerable to oxidative stress in stroke. We believe that cl-
nanozyme is a promising delivery strategy that can find application in the therapy of 
cerebrovascular conditions associated with oxidative stress and inflammation. Evaluation of 
cl-nanozyme safety and efficacy in alternate models of transient ischemic stroke, e.g. 
MCAO procedure conducted on aged animals and/or animals with co-morbidities, is 
essential for further validation of the translational potential of this work.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distribution of Cl-nanozyme in the Rat Brain
Distribution of cl-nanozyme in the ipsilateral hemisphere of rat brains after I/R injury 
determined by immunofluorescence. A. Cl-nanozyme (PEG, green) was detected primarily 
in association with micro vessels (PECAM-1, red). B. Most cl-nanozyme signal co-localized 
with fibrin in rat brains after stroke, indicating possible interactions between cl-nanozyme 
and thrombus components. C. Not all fibrin signal in the brain were co-localized with cl-
nanozyme. Nuclei are counterstained with DAPI, scale bars represent 20 µm.
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Figure 2. Cl-nanozyme Accumulation in the Damaged Internal Carotid Artery (ICA)
The ICA in the ipsilateral hemisphere in the rat brain showed intense staining for cl-
nanozyme, which was not observed in the contralateral hemisphere. A. The ICA in the 
ipsilateral hemisphere was the only artery that showed very strong cl-nanozyme staining in 
the whole brain; B. 2.5× magnification of the squared area in A. Sub-arachnoid region 
shows that this staining was present only in the ipsilateral hemisphere, but not in the 
contralateral hemisphere; C. Confocal image of this artery shows cl-nanozyme co-
localization with the injured endothelium cells lining the internal surface of this artery. Scale 
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bars represent 20 µm. D. A graphic illustration of the position of the brain section shown in 
A.
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Figure 3. Distribution of Cl-nanozyme in Rat Peripheral Organs
Representative bright field micrographs of tissue sections harvested from MCAO rats 24 h 
after reperfusion. DAB was used to visualize cl-nanozyme in the tissue sections (black 
arrows). Scale bar represents 50 µm. B. Representative confocal fluorescent micrograph of 
liver tissue sections harvested from stroke rats 24 h after reperfusion and cl-nanozyme 
administration. Fluorescent immunohistochemistry demonstrated cl-nanozyme micro-
distribution within the liver: red – hepatocytes; pink - Kupffer cells; green – cl-nanozyme; 
blue – nuclei. Scale bar represents 10 µm. Treatment groups are the same as shown in A.
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Figure 4. Biodistribution and Serum Clearance of Native SOD1 and Cl-nanozyme in healthy 
mice
A. C57BL/6 mice received IV bolus injection of either 125I-labeled native SOD1 (n=7), or 
cl-nanozyme (n=8). One hour later organs were harvested and radioactivity was measured. 
Results represent mean % of injected dose per gram of tissue (ID%/g) with error bars 
representing ±SEM. Statistical significance was determined by Student’s t-test (indicated as 
follows: n.s., not significant; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001); B. 
Serum clearance profiles of native SOD1 and cl-nanozyme were plotted and analyzed by 
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linear regression fitting. The serum half-life was 33.8 min (R2=8966, P<0.0005; n=1–2 
mice/time point) for cl-nanozyme, and 10.3 min (R2=8156, P<0.05; n=1–2 mice/time point) 
for native SOD1.
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Figure 5. Therapeutic Efficacy of Cl-nanozyme in Mice MCAO Model of I/R Injury
At the onset of reperfusion, 10,000 U/kg of native SOD1 (n = 8), cl-nanozyme (n = 8), or 
equal volumes of saline (n = 7) were injected through the right jugular vein of the mice 
under anesthesia. Twenty-four hours after reperfusion, mice were euthanized and their 
brains were sectioned and stained using TTC solution. A. Bar graph showing infarct volume 
reduction. Infarction (% contralateral) was quantified as described in the methods section. 
Data were analyzed using one-way ANOVA with Tukey’s post-hoc test and presented as 
mean ± SEM. Statistical significance is defined as P<0.05, and indicated by * (P<0.05), ** 
(P<0.01), or **** (P<0.0001). B. Representative coronal brain sections from animals 
receiving different treatments stained using TTC. Dark-colored areas indicate viable tissue; 
pale-colored areas indicate dead (infarcted) tissue.
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Figure 6. Thrombus Incorporation Assay in Mouse Plasma
Native SOD1 and cl-nanozyme were labeled using 125I before incubation with mouse 
plasma for 24 h at 4 °C. The plasma was then centrifuged to separate thrombus and serum. 
The percentage of radioactivity in the thrombus compartment was calculated as described in 
the methods section. BSA and fibrinogen were also labeled and used in parallel as negative 
and positive controls. Data were analyzed using unpaired Student’s t-test and are presented 
as mean ± SEM (n=4 or 5). Statistical significance is defined as P<0.05, and indicated by 
n.s. (not significant) or **** (P<0.0001).
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